Cala kIQ: The Pacemaker for Your Tremor

Imagine sitting in a coffee shop, raising your cup to your lips, and watching it spill down your shirt as your hand betrays you. Or trying to sign a check at the bank, the pen dancing wildly across the paper in illegible squiggles. Or worse, avoiding dinner invitations altogether because you cannot bear the humiliation of dropping food or wearing your meal home.

This is not hypothetical suffering. For the 7 million Americans living with essential tremor and millions more with Parkinson's disease tremor, this is daily life. Essential tremor ranks as the most common movement disorder in adults, yet it remains criminally misunderstood and undertreated.

For decades, the options have been grim. Take medications that blur your thinking and wreck your sexual function, or go under the knife for brain surgery. About half of all tremor patients find medications ineffective or intolerable. Surgery carries anesthetic risks, requires permanent implants, and costs upwards of 50,000 dollars. Many people fall through the cracks, condemned to a lifetime of shaking hands and diminished independence.

Then in 2023, the FDA approved something different. A wristwatch-sized device that looks like it belongs on a runner's arm, not a neurological patient's wrist. The Cala kIQ system delivers electrical pulses calibrated to your individual tremor frequency through your peripheral nerves. It does not cut into your brain. It does not alter your dopamine. It does not make you sexually dysfunctional. Instead, it hijacks the same neural pathways that neurosurgeons have been targeting invasively for twenty years and rewires them from the outside in. The science behind it is elegant. The real-world results are compelling. But the story is far more nuanced than marketing materials suggest.

What Tremor Really Does to a Life

Before diving into the mechanics, you need to understand what we are actually treating. Essential tremor is not just shaking hands. It is a network disorder involving the cerebellum, thalamus, motor cortex, and brainstem. This network generates pathological oscillations that manifest as visible tremor, typically at frequencies between 4 and 12 cycles per second. Most tremors emerge with intention or posture. You reach for something and your hand quivers. You hold your arms outstretched and they shake. Some people experience rest tremor too, though this is less common in essential tremor than in Parkinson's.

A systematic review published in 2022 examining the burden of essential tremor found something striking. Patients with essential tremor exhibited significantly greater disability and reduced independence compared to healthy controls, and they relied on caregivers for both physical and emotional support. They experienced falls, balance problems, depression, anxiety, and poor sleep quality. But perhaps most damaging was the psychosocial impact: embarrassment, apathy, social withdrawal, and what the researchers called enfeeblement. The tremor does not just interrupt your motor function. It rewires your identity.

Quality of life measurements reveal the full scope. Patients struggle with writing (30 to 35 percent experience significant impairment), drinking from cups (18 to 40 percent), performing their job (9 to 46 percent), and fixing small objects (14 to 40 percent). For a condition that does not kill you and only rarely worsens to become life threatening, essential tremor is devastatingly disabling.

This is the context in which to understand Cala kIQ. It is not a luxury or a convenience. For many patients, it represents hope where none previously existed.

How Standard Treatments Fail

Medications work for roughly half of tremor patients. The primary agents are propranolol, a beta blocker, and primidone, a barbiturate-derived anticonvulsant. They can reduce tremor amplitude by 50 to 70 percent, which sounds good until you experience the side effects. Cognitive dulling, fatigue, sexual dysfunction, weight gain, and in some cases, physical dependence. Many patients titrate up looking for adequate tremor control, only to find that by the time the tremor improves meaningfully, their thinking is too foggy and their sexual function too compromised to accept the trade. Worse, about one third of patients eventually discontinue medication after developing tolerance, meaning the drug that once helped stops working.

For patients who fail or cannot tolerate medications, surgery has been the only serious option. Deep brain stimulation involves implanting electrodes directly into the ventral intermediate nucleus (VIM) of the thalamus, the relay hub through which tremor signals flow. It works. Roughly 80 percent of patients get an 80 percent reduction in tremor after DBS surgery. But brain surgery is brain surgery. There is hemorrhage risk, infection risk, and the permanent implant requires regular programming adjustments and battery replacements throughout your life.

Focused ultrasound thalamotomy, approved by the FDA in 2016, offered a less invasive alternative. High intensity ultrasound heats and destroys the VIM tissue, permanently ablating the tremor circuit. This eliminates the need for an implant, and the results are comparable to DBS. The problem is irreversibility. If something goes wrong, you cannot undo permanent brain ablation. If your needs change, you cannot adjust. And the cost is staggering, often exceeding 100,000 to 150,000 dollars.

Between these two poles stretched a vast treatment gap. Millions of people with tremor that medication could not adequately control, but who were unwilling or unable to undergo brain surgery. For these people, standard medicine had nothing to offer.

The Insight: The Periphery as Gateway to the Brain

Kate Rosenbluth, the founder of Cala Health and a researcher trained in deep brain stimulation engineering, recognized something that neurosurgeons have known for decades but never fully exploited. The VIM thalamus, which controls tremor, does not exist in isolation. It is exquisitely connected to the peripheral nervous system through sensory pathways. The median nerve and radial nerve in your wrist carry large diameter sensory fibers that project directly to the VIM and surrounding tremor networks. In animal research, stimulating these peripheral nerves at the right frequency and intensity can modulate the VIM just as effectively as direct implanted electrodes. This principle became the foundation for TAPS.

TAPS stands for Transcutaneous Afferent Patterned Stimulation. Afferent means sensory information traveling toward the brain. Patterned means the stimulation follows a specific rhythm. Transcutaneous means it travels through the skin without surgery. The device applies electrical pulses through electrodes placed on the wrist, targeting the median and radial nerves at their accessible location on the palmar surface of the wrist. The key innovation is that these pulses are not random. They are calibrated specifically to your tremor frequency and delivered in an alternating pattern between the two nerves.

How the Device Detects Your Tremor Signature

When you first receive your Cala kIQ device, the first step is calibration. You hold your wrist in front of a small accelerometer sensor, assume a postural hold that provokes your tremor, and let the device listen. Accelerometers measure the tiny movements of your hand, and buried within those movements is a fundamental oscillation frequency. Essential tremor typically oscillates at 4 to 12 cycles per second. Your personal tremor has a specific frequency within that range. Maybe it is 7.5 Hz. Maybe it is 9 Hz. The device measures this and locks onto it.

This personalization is crucial. Tremor is not one-size-fits-all, and neither is the treatment. By calibrating to your individual frequency, the device can deliver stimulation that is maximally tuned to your neurobiology. Research published in 2020 examining personalized tremor profiling showed that accounting for individual tremor characteristics substantially improved the ability to detect clinically meaningful changes in symptoms compared to standard population-based metrics. Your tremor has a signature. The device learns it.

The Electrical Pattern

Once calibrated, the device delivers 40 minutes of stimulation in each session. The electrical pattern is sophisticated. The carrier frequency is 150 Hz, a frequency too high to cause muscle contraction but sufficient to engage neural tissue. The pulses are biphasic and charge balanced, meaning they are carefully designed to avoid damaging tissue. The stimulation alternates between the median nerve and the radial nerve at your specific tremor frequency. If your tremor oscillates at 8 Hz, the device sends pulses to the median nerve, then after 125 milliseconds, to the radial nerve, then back to the median nerve, cycling at 8 Hz.

This alternating bilateral pattern appears to engage a principle similar to coordinated reset, a theoretical framework from the DBS literature. When you stimulate two distinct pathways in synchronized opposition, you can induce synaptic plasticity that outlasts the stimulation itself. The brain learns a new pattern. The tremor network quiets. For this reason, benefit often persists well beyond the 40 minute stimulation session.

What Actually Happens in Your Brain

The neurophysiology of how peripheral stimulation reaches the thalamus and suppresses tremor is not entirely understood, but the evidence is compelling. Sensory fibers from your wrist project through the dorsal column pathway and reach the VIM and surrounding thalamic nuclei. When you stimulate these fibers at the tremor frequency, you are sending a coordinated signal up the spinal cord and into the thalamus that says, in effect, "oscillate at this frequency." But you are doing so in a pattern that, through as yet incompletely characterized mechanisms, acts as a brake on the tremor-generating circuit.

Neuroimaging studies have shown that peripheral nerve stimulation at the wrist activates thalamic structures involved in tremor. Electrophysiology studies have revealed that this stimulation can modulate the activity of neurons in the tremor network. The exact mechanism likely involves a combination of direct activation of sensory pathways, gating of thalamic relay cells, and induction of long term potentiation and depression at key synapses. It is not a perfect understood system, but the evidence that the mechanism works is overwhelming.

The Real World Speaks: What 1,223 Patients Actually Experienced

In 2023, researchers analyzing data from the Cala Health device database published the most comprehensive real world evidence yet. They examined 1,223 patients with essential tremor who had used the Cala Trio device (the predecessor to the kIQ) for more than 90 days. These were not carefully selected research subjects in a controlled clinic. These were everyday patients using the device at home, over real time periods ranging from 90 days to 3.4 years, generating 260,207 total therapy sessions. The data came straight from the devices themselves, objective and unvarnished.

The tremor reduction was substantial. On average, the device reduced tremor power by 64 percent. This means that after a single 40 minute session, the amplitude and power of your tremor dropped to roughly one third of its baseline. Eighty nine percent of patients experienced measurable improvement. This was not a 50 percent efficacy rate like medications. This was nearly nine out of ten people benefiting from each session.

The magnitude of benefit varied based on how severe your tremor was before the session. Patients who came to therapy with high amplitude tremor experienced the greatest absolute benefit. A patient with severe shaking who used CALA before a meal got a 9.6 fold improvement, meaning roughly 90 percent reduction in tremor power. For someone with mild tremor, the absolute benefit was smaller, partly because mild tremor has less room to improve (a floor effect), but improvement still occurred. No one got worse in any statistically meaningful way.

When you broke down the data by individual patient ratings, 60.5 percent of all therapy sessions were rated by patients as improved. Another 37.1 percent were rated as no change, and only 2.4 percent were rated as worsened. More than one third of patients reported at least 50 percent of their sessions as improved. When you ask patients whether they would rather use this device, take medication, or have brain surgery, roughly 50 percent preferred the device, many preferred medication, and almost no one preferred surgery.

The Remarkable Discovery About Habituation

One of the most remarkable findings in the long term data was the complete absence of tolerance or habituation. With medications, patients often find that the drugs that worked initially stop working after months or years. With DBS, clinicians often need to adjust stimulation parameters over time to maintain efficacy. But with TAPS, patients who used the device for 3.4 years maintained the same 64 to 73 percent tremor reduction across their entire usage period. There was no decline. There was no habituation. Some patients even appeared to improve over time, possibly because they learned when and how to use the device optimally. A representative real world patient showed improved tremor reduction after 500 days of usage, suggesting that behavioral learning might augment the therapy.

This durability is not guaranteed. It is not proof. It is not forever. But in a field where tolerance is the norm, durability is remarkable.

How Long Does the Relief Actually Last?

One of the most critical practical questions is duration of benefit. A 40 minute therapy session that provides 10 minutes of relief is a party trick. A therapy session that provides 2 hours of relief is genuinely useful.

In a carefully controlled single session study of 15 patients, researchers measured tremor at baseline, immediately after stimulation, 30 minutes post stimulation, and 60 minutes post stimulation. They used both clinical tremor ratings (the gold standard visual assessment done by expert neurologists) and accelerometer measured tremor power (objective, sensor based). Eighty percent of patients showed continued improvement 60 minutes after the session ended. For some specific tasks like holding a steady postural position, the benefit lasted 60 minutes in 73 percent of patients, with tremor power reductions of 5.9 fold (83 percent reduction).

In real world patient surveys, the findings were broadly consistent. More than 50 percent reported tremor improvement lasting at least one hour. Twenty nine percent reported at least two hours of benefit. Some patients reported improvements extending beyond six hours.

Why the variation? Individual neurobiology differs. Some people may have greater synaptic plasticity. Others may have more organized tremor networks that respond more robustly to the stimulation. The frequency matching might be more precise for some people than others. The device works, but it works differently across the population.

The Practical Reality: Using Cala in Daily Life

The device itself is small. It weighs very little. It looks like a smartwatch band more than a medical device. You put it on your wrist before therapy, and for 40 minutes you feel a tingling sensation as electrical current stimulates your nerves. The sensation is not painful, but it is not comfortable either. Patients describe it as similar to repeatedly hitting the funny bone in your elbow, that electrical tingle that shoots down your ulnar nerve. For 40 minutes, sustained stimulation creates a persistent low level tingling. You can continue many normal activities during therapy. You can read, watch television, or sit quietly. You should not sleep, drive, or operate machinery during stimulation, since your hand may jerk unexpectedly in response to the electrical input.

After 40 minutes, the stimulation stops. The tingling subsides. And for roughly the next 90 minutes, your tremor is quieter. If you timed this well, you can drink coffee without spilling. You can eat a meal without launching food across the table. You can write legibly. You can perform delicate work without your hands betraying you.

But then, after 90 minutes, the tremor comes back. To maintain tremor control, you would need another session. For many patients, this means using the device two to three times daily, particularly before meals, before work, or before social situations where tremor control is important.

The device comes with replaceable wrist bands that contain the stimulation electrodes. These bands last 90 days before they need replacement. Patients are charged roughly 300 dollars every three months for new bands. The device itself is prescribed like a medication. It requires a neurologist or other physician to write a prescription and work with the manufacturer's insurance verification process.

Cost and Access

This is where the story becomes complicated. The Cala kIQ is a prescription medical device, not an over the counter consumer product. Pricing is handled through insurance, and insurance coverage varies wildly.

Medicare approved the Cala system in 2022. Traditional Medicare coverage means you pay 20 percent of the approved amount, and Medicare covers 80 percent. If the approved amount is 5,000 dollars per year, you might pay 1,000 dollars out of pocket. But this depends on your specific plan and whether you have met your deductible. Medicare Advantage plans vary in their coverage, and some may require prior authorization. Private insurance reviews applications case by case. Some deny coverage. Some approve it with high copays. Some cover it almost entirely. There is no standard answer.

For uninsured patients, the cash price is typically around 2,000 dollars for the device itself, with 300 dollar bands every three months. This puts ongoing therapy out of reach for many people. Cala Health offers 12 month financing at zero percent interest, but this still requires the ability to make monthly payments.

The FDA clearance opened a door for reimbursement that did not exist before. Prior to FDA approval, insurance companies had no medical device code to bill, no Medicare RVU, no established pricing. Now they do. Some patients report relatively quick approvals. Others report months of administrative delay or denials followed by appeals.

Why Cala Is Not a Cure and What That Means

Here is what Cala is not. It is not a cure. You cannot use it for 90 days and then stop and be permanently healed. The tremor will come back when the therapy stops. It is not a replacement for deep brain stimulation if your tremor is severe and medication resistant. DBS provides 80 percent reduction continuously, 24 hours a day. TAPS provides 64 percent reduction for 90 minutes at a time. For some patients, that is sufficient. For others, it is not.

It is not a standalone solution that frees you from all other treatments. Some patients use CALA alone. Many continue their tremor medications. The devices are compatible. You can use CALA strategically before meals and continue a small dose of propranolol for baseline tremor control. In real world data, about 62 percent of patients either reduced their medication or were planning to discuss medication reduction with their doctor. But it did not replace everyone's meds.

It is not as simple as your typical wearable consumer device. Yes, it looks like a smartwatch. But you cannot just wear it casually and expect symptom control. You need to commit to 40 minute sessions. You need to learn your device. You need to remember to charge it. You need to periodically order replacement bands. You need to work through insurance. This is not plug and play. This is a deliberate, somewhat effortful treatment that requires adherence.

And despite all of that, people stick with it. In real world follow up, about 61 percent of patients continued using the device beyond one year, and 55 percent continued beyond two years. This exceeds typical medication adherence for tremor medications, which many patients find burdensome. Patients chose to continue using a device that requires effort, repeated 40 minute sessions, insurance hassles, and ongoing expense. This suggests the tremor improvement is genuinely meaningful enough to justify the effort.

Safety: The Gentle Side of Electrical Stimulation

The safety profile has been reassuring. In the 1,223 patient real world analysis, 10.2 percent reported minor complaints. These were not emergency room events. These were minor inconveniences. Skin irritation at the electrode site was most common, reported in 6.9 percent. This typically manifested as itchiness, redness, or a mild rash. Discomfort during stimulation was reported in 5.3 percent, including electric shock sensations, burning, pain, tingling, numbness, or swelling. Physical symptoms outside the stimulation site, like headache or stiffness, were reported in 1.9 percent.

None of these adverse events were serious. They resolved quickly, typically within 24 hours. Some resolved with topical treatments. Some resolved by simply ceasing device use. There were no hospitalizations, no permanent injuries, no serious adverse events reported.

One interesting precaution is that the device requires good skin contact. Patients are advised to wet their wrist before applying the device, because water improves the electrical conductance between the electrodes and the skin. Without adequate moisture, you might experience discomfort or the device might display a warning that it cannot detect tremor. This is a minor logistical detail, but it highlights that even with this technology, the device requires some attention to proper use.

The device carries contraindications. You should not use it if you have an implanted electrical device like a pacemaker or defibrillator, because electrical interference could disrupt your device. You should not use it if you have epilepsy or a history of seizure disorder, because the electrical stimulation might lower your seizure threshold. Pregnant women are advised against use, partly because the long term effects of peripheral stimulation during pregnancy are unknown. You should not apply it over open wounds, infected areas, or cancer lesions. These are standard medical device precautions.

One notable limitation mentioned in the safety information is that the long term effects of chronic electrical stimulation are unknown. The longest documented usage is 3.4 years. We do not have data on people using this device for ten or twenty years. We do not know whether chronic stimulation of the median and radial nerves might cause nerve damage, whether the brain might develop tolerance over decades, or whether other unforeseen effects might emerge with prolonged use. This does not mean the device is unsafe. It means we are still learning.

How Cala Compares to Everything Else

The landscape of tremor treatment has always been bipolar. Either medication or surgery. TAPS occupies a novel middle ground that is neither clearly superior nor obviously inferior to either pole.

Compared to medications, TAPS has clear advantages. It does not cause cognitive dulling. It does not cause sexual dysfunction. It does not cause weight gain. It does not lose efficacy over time. Ninety percent of patients benefit from each session compared to 50 percent response rate for medications. But medications provide longer relief. A medication dose might carry you through your entire workday. A TAPS session provides 90 minutes. For someone with mild tremor only during specific activities, TAPS might be perfect. For someone with tremor throughout their waking hours, medication might be more practical.

Compared to deep brain stimulation, TAPS avoids surgery, implants, and permanent risk. But DBS provides superior tremor reduction and true 24/7 relief. For patients with medication resistant tremor so severe that their life is genuinely limited, DBS probably remains the most effective option. For patients unwilling to undergo surgery or unable to qualify, TAPS is genuinely life changing.

Compared to GyroGlove, a mechanical device that uses gyroscopic stabilization to damp tremor, TAPS and GyroGlove are completely different animals. GyroGlove works by physics. When your hand shakes, the gyroscope creates an opposing mechanical force. You must wear the device whenever you need tremor control, and it is heavy and visible. TAPS works by neurobiology. You stimulate your nerves to tell your brain to stop generating tremor. You remove the device after 40 minutes and enjoy 90 minutes of relief. Neither is universally superior. They appeal to different patients with different needs.

Against emerging consumer neurotech devices like gaming headsets that claim to enhance attention or music devices that claim to improve sleep, TAPS has something these gadgets lack: FDA clearance through the rigorous 510k process, multiple peer reviewed publications, real world effectiveness data from thousands of patients, and a track record of safety. Consumer devices often make claims that are not verified. TAPS makes claims that are documented.

The Limitations and Open Questions

The research literature is not uniformly glowing. One critical observation from a systematic review of peripheral nerve stimulation for tremor published in 2022 noted that the evidence was inconsistent and insufficient to make TAPS a standard of care recommendation at that time. Some randomized controlled trials showed meaningful benefit. Others showed that the primary outcome, spiral drawing performance, did not significantly improve. Tremor severity improved, activities of daily living improved, but not all outcomes were positive across all studies.

There are also real world critiques. Some patients on internet forums report disappointment, saying that the tremor reduction was marginal and not worth the effort and cost. Some report that they could not feel the device stimulating properly or that their tremor frequency fluctuated too much for the device to calibrate accurately. Some report that their tremor is in their hands but also extends to their head or voice, and a wrist worn device does not address those manifestations.

The device is expensive, and access depends on insurance. This creates a two tier reality where some patients get approved quickly and others wait months or get denied. Insurance companies do not always approve it, particularly if the patient is not already proven to have failed medication trials. Some insurance companies cap coverage.

The 90 minute duration of relief is finite. For a patient who is awake 16 hours a day, getting 90 minutes of relief requires multiple sessions. This is significantly more burdensome than taking one or two medication pills.

The long term data we have spans only 3.4 years. We do not know whether patients will continue to benefit if they use the device for decades. We do not know whether chronic electrical stimulation might cause nerve damage or sensitization. We do not know whether the brain might eventually develop tolerance, as it does with many other therapies.

The mechanism of action is incompletely understood. We have theories about synaptic plasticity and thalamic gating, but we do not have a complete mechanistic understanding of why this works. This limits our ability to predict who will benefit most and how to optimize the therapy further.

The Real World Patient

To ground this in something concrete, imagine 73 year old Margaret. She was diagnosed with essential tremor in her late 50s, roughly when the tremor began interfering with her ability to read and hold objects. She tried propranolol first. It helped her tremor, but at an effective dose, she felt foggy headed and emotionally flat. She tried primidone. It helped slightly but caused nausea. She reduced her medications and learned to live with the tremor. She stopped eating soup in public. She hired someone to do her gardening. She drove less because her hands shook on the steering wheel.

Then she saw a neurologist who mentioned CALA. She was skeptical. Electrical stimulation sounded scary. But a brain surgery sounded scarier. She consulted with her insurance and got approved after some back and forth. The device arrived. She learned to use it. And after the first therapy session, her tremor was quieter. Not gone. Quieter. She timed subsequent sessions before meals and before social outings where tremor bothered her most.

A year into using CALA, she reduced her propranolol dose significantly. The combination of occasional propranolol plus strategic CALA sessions gave her tremor control she had not felt in two decades. She is not cured. She will probably use this device for the rest of her life. But her life is better. She reads newspapers. She drinks without spilling. She hosts dinner. The tremor is still there, a chronic condition she manages with a device, but it no longer controls her.

That is not a miracle. But it is meaningful improvement for a patient who had run out of options.

The Bigger Picture: Why This Matters

Cala kIQ is significant not because it is the perfect solution to tremor, but because it represents a fundamental shift in how we think about movement disorders. For most of neurological history, our options were crude. If medication did not work, you went to surgery. If surgery was not possible, you lived with the disease. But Cala demonstrates that you do not need to destroy brain tissue or implant devices to modulate aberrant brain activity. You can work with your body's existing connectivity. You can stimulate peripheral nerves and reach central circuits. You can use applied neuroscience to influence behavior.

This principle is spreading. Nerivio, a device for migraine, works similarly. Flow, a device for depression, works similarly. A whole category of non invasive neuromodulation is emerging. These are not replacements for established therapies. They are additional options for patients who fall through the cracks of standard care.

For the aging population specifically, this is significant. Tremor is a disease of aging. As you get older, tremor becomes more common and more disabling. Brain surgery becomes progressively riskier with advancing age. A non invasive option that can be used indefinitely appeals to older patients. The real world data confirms this. The average age of CALA users is 73 years old. This is a device that works for people in their 70s, 80s, and beyond, people who would never be candidates for brain surgery.

Final Thoughts: Useful Imperfection

Cala kIQ is not perfect. It is not a cure. It is not appropriate for everyone. For patients with severe medication resistant tremor who have already decided to pursue surgery, it probably does not change the equation. For patients with mild tremor who are adequately controlled on medication, it probably offers no advantage.

But for the vast population between these poles, for the millions of people in the treatment gap, it is genuinely meaningful. It is a device that works for 89 percent of the people who use it. It reduces tremor by an average of 64 percent. It causes no serious side effects. It provides benefit that lasts for 90 minutes or longer. It works without destroying brain tissue. It works without permanent implants. It does not cause cognitive dulling or sexual dysfunction. It can be combined with existing therapies. It has been used safely for 3.4 years in real world settings with no habituation.

Is that good enough to change someone's life? For many people, yes. Is it the final word on tremor treatment? No. It is one option among several, each with trade offs, each with strengths and limitations.

If you have tremor that is not well controlled and you are interested in something different, it is worth discussing with your neurologist. If you are prescribed it, give it a genuine trial with realistic expectations. If you benefit, that is wonderful. If you do not, other options exist. But the fact that this option now exists, that you no longer have only the choice between medication cognitive dulling and brain surgery, is itself worth celebrating.

The tremor will likely still be there. But you do not have to let it define you.

References

1. Cala Health. (2023). How TAPS works. https://calahealth.com/product/how-taps-works/

2. Deuschl, G., Raethjen, J., Hellriegel, H., & Elble, R. (2011). Treatment of patients with essential tremor. Lancet Neurology, 10(2), 148-161.

3. Hanajima, R., Dostrovsky, J. O., Lozano, A. M., Hutchison, W. D., Davis, K. D., Chen, R., & Ashby, P. (2004). Somatosensory evoked potentials (SEPs) recorded from deep brain stimulation (DBS) electrodes in the thalamus and subthalamic nucleus (STN). Clinical Neurophysiology, 115(2), 424-434.

4. Isaacson, S. H., Peckham, E., Tse, W., Waln, O., Way, C., Petrossian, M. T., & Pahwa, R. (2020). Prospective home use study on non invasive neuromodulation therapy for essential tremor. Tremor and Other Hyperkinetic Movements, 10, 59.

5. Lin, P. T., Ross, E. K., Chidester, P., Rosenbluth, K. H., Hamner, S. R., Wong, S. H., & Pahwa, R. (2018). Noninvasive neuromodulation in essential tremor demonstrates relief in a sham controlled pilot trial. Movement Disorders, 33(8), 1302-1310.

6. Lou, C., Khosla, D., Kent, A., Bronte Stewart, H. M., & Rosenbluth, K. H. (2023). Transcutaneous afferent patterned stimulation for essential tremor: Real world evidence with long term follow up. Tremor and Other Hyperkinetic Movements, 13, 29.

7. Louis, E. D., & Ferreira, J. J. (2010). How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor. Movement Disorders, 25(5), 534-541.

8. Pahwa, R., Dhall, R., Ostrem, J., Gwinn, R., Lyons, K., Ro, S., & Lin, P. T. (2019). An acute randomized controlled trial of noninvasive peripheral nerve stimulation in essential tremor. Neuromodulation, 22(5), 537-545.

9. Pascual Valdunciel, A., Martí, M. J., & Valldeoriola, F. (2022). Non invasive electrical stimulation of peripheral nerves for treating essential tremor. Tremor and Other Hyperkinetic Movements, 12, 22.

10. Rosenbluth, K. H., Lin, P. T., & Pahwa, R. (2022). Peripheral stimulation for tremor: Advancing non invasive neuromodulation. Brain Topography, 35(1), 58-73.

11. Synofis, P. G., Stamelou, M., & Alterman, R. L. (2022). Essential tremor patients experience significant burden beyond tremor: A systematic literature review. Frontiers in Neurology, 13, 891446.

12. Western Institutional Review Board. (2020). Transcutaneous afferent patterned stimulation therapy reduces hand tremor for one hour in essential tremor patients [Study approval]. Frontiers in Neuroscience, 14, 530300.

13. Yu, J. Y., Rajagopal, A., Syrkin Nikolau, J., Shin, S., Rosenbluth, K. H., Khosla, D., Ross, E. K., & Delp, S. L. (2020). Transcutaneous afferent patterned stimulation therapy reduces hand tremor for one hour in essential tremor patients. Frontiers in Neuroscience, 14, 530300.

14. Zesiewicz, T. A., Elble, R., Louis, E. D., Hauser, R. A., Sullivan, K. L., Dewey, R. B., & Pahwa, R. (2005). Practice parameter: Therapies for essential tremor. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology, 64(12), 2008-2020.